The World s First Published Expert Consensus on ARNI Treatment For Hypertension
Chinese Expert Recommendation On The Clinical Application Of Sacubitril/Valsartan in Patients With Hypertension
Perspectives
A
The Chinese Expert Consensus Recommendations on the Clinical Application of Sacubitril/valsartan in Patients With Hypertension document was recently published in the
Chinese Journal of Hypertension (2021; 29(2): 108-114). The recommendations were jointly compiled by the hypertension branch of the China International Exchange and Promotive Association for Medical and Health Care, the cardiovascular branch of the Chinese Medical Doctor Association, and the Chinese Hypertension League. Because it is the first expert consensus on the treatment of hypertension using angiotensin receptor neprilysin inhibitor (ARNI), it is expected to serve as an important reference for developing standardized clinical application protocols for this drug.
ACC Announces Late Breaking Studies at 2021 Meeting dicardiology.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dicardiology.com Daily Mail and Mail on Sunday newspapers.
email article
As two drugs that technically failed in clinical trials for heart failure with preserved ejection fraction (HFpEF) head into an FDA advisory panel gauntlet, reviews by agency staff give some reason for optimism.
Sacubitril/valsartan (Entresto), which gets an all-day grilling by the Cardiovascular and Renal Drugs Advisory Committee on Tuesday, missed its primary endpoint in the PARAGON-HF trial. It failed to reduce HF hospitalization and death from cardiovascular causes versus valsartan alone in those with a left ventricular EF of 45% or higher (RR 0.87,
P=0.06).
Spironolactone (Aldactone), headed for a part-day review by the same committee on Wednesday, likewise failed the primary endpoint in the TOPCAT trial. It didn t reduce death from cardiovascular causes, aborted cardiac arrest, or HF hospitalization in those with an EF of 45% or more compared with placebo (HR 0.89,